Shares tumble after late-stage trial failure
Karyopharm Therapeutics experienced a dramatic intraday decline after its late-stage endometrial cancer trial did not meet its primary objective. In morning trading the stock fell 67.3% to trade at $2.29 following the company's announcement that the Phase 3 XPORT-EC-042 study failed to achieve a statistically significant improvement in progression-free survival versus placebo.
The XPORT-EC-042 trial evaluated selinexor as a maintenance therapy in patients with TP53 wild-type advanced or recurrent endometrial cancer. While the selinexor arm showed a numerical advantage in progression-free survival of more than five months compared with placebo, that difference did not reach statistical significance for the primary endpoint.
Corporate response and reallocation of resources
Following the trial results, Karyopharm said it will scale back planned investment in the endometrial cancer program and reallocate resources toward its myelofibrosis and multiple myeloma franchises. The company separately confirmed plans to submit a supplemental New Drug Application to the FDA in August 2026 for selinexor in combination with ruxolitinib for myelofibrosis using an accelerated approval pathway, and that a Priority Review request will be included with that submission.
Analyst reactions and valuation reassessments
Analysts responded quickly and with sizeable downgrades. Baird lowered its rating from Outperform to Neutral and reduced its price target from $15.00 to $3.00. H.C. Wainwright moved its rating from Buy to Neutral and cut its target from $13.00 to $3.00. Both firms cited the loss of a key growth catalyst as the rationale for the reduced outlook and targets.
Market context and intraday trading
The broader U.S. benchmarks - the S&P 500, Dow Jones, and NASDAQ - traded modestly lower during the session, offering little support as investors processed corporate earnings and shifting economic expectations. That cautious market backdrop provided limited appetite to absorb a widely followed clinical disappointment of this scale.
The combination of the late-stage trial miss, immediate reassessment of the company's pipeline value, and rapid analyst cuts produced one of Karyopharm's steepest single-session declines on record. Shares hit a new 52-week low of $2.09 intraday before a partial rebound returned the price to $2.29 in the morning session.
What this means for investors
The clinical outcome removed a proximate catalyst that had been factored into investor expectations and analyst models, prompting rapid downward revisions to near-term valuation. Management's decision to redirect investment toward other therapeutic areas leaves the company pursuing a separate regulatory timetable in myelofibrosis while de-emphasizing the failed endometrial program.
As markets continue to weigh corporate results and economic signals, the immediate market response to Karyopharm's announcement underscores the sensitivity of biotech valuations to late-stage clinical readouts and the role of analyst guidance in short-term price discovery.